Daniel Grant
Head of Strategic Alliances
Barbara Dalton is a Pharmaceutical executive who has spent over 20 years in the industry - most of that time as a corporate venture capitalist.
At Pfizer she is responsible for growing their corporate venture activities, managing the current equity portfolio and advising on structured equity transactions. She was trained as a research scientist in a virology and immunology laboratory at The Medical College of Pennsylvania where she received her Ph.D. She pursued inflammation drug discovery research at SmithKline's research laboratories and joined their venture capital group, S.R. One, Limited in the early 1990's. While there Barbara Dalton was a founding member of Euclid SR Partners, a private New York based venture capital firm where SmithKline (now GSK) was a leading limited partner. She joined that firm full time in 2003. Last year she moved to her current position at Pfizer.
Barbara Dalton has managed over 20 fund investments and 60 diverse company investments in the US and Europe and has had direct investing responsibility for biotechnology therapeutic and platform technology companies, as well as some healthcare IT and service businesses. In the community she has been active in her regional venture investors association, the MAC Alliance, serving most recently as Chairman, and supported the venture philanthropy efforts of the Institute for the Study of Ageing as a board member.
She is an advisor to the Dean of the Eberly College of Science, where she received her undergraduate degree, and a new member of The Penn State Research Foundation Board of Directors. She is also a member of the board of the New York Biotech Association and the National Venture Capital Association.
Dr. Daniel Grant is the Head of Strategic Alliances for PfizerAustralia. In collaboration with colleagues in Pfizer's Worldwide Business Development team, he is responsible for identifying and managing collaborative opportunities that arise from Australia's research landscape that align with Pfizer's strategic direction.
Prior to joining Pfizer, Dr Daniel Grant was a Senior Business Development Manager at Melbourne Ventures Pty Ltd, the commercialisation arm of the University of Melbourne, and the University of Melbourne's representative on the Investment Committee of Uniseed Pty Ltd, a pre-seed investment company for the Universities of Queensland, NSW and Melbourne. Dr Daniel Grant has sat on the board of a number of biotechnology spin-out companies and was the Commercialisation Manager at Biocomm Services Pty Ltd, a company established by the Victorian State Government to bridge the gap between research, academia and the commercial world. Dr Daniel Grant has M.Sc. in Respiratory Physiology, a Ph.D. in Cardiovascular Physiology and an MBA. He has more than 15 years experience in applied biomedical research in Canada and Australia.